Frontier Medicine
TIL-терапія переводить клітинну онкологію в персоналізоване виробництво
СигналFDA approved Amtagvi, a tumor-derived autologous T cell immunotherapy for previously treated unresectable or metastatic melanoma.
ПатернOncology is shifting from standardized drug delivery toward patient-specific biological manufacturing, where treatment is assembled from the patient's own tumor and immune cells.
НаслідокCancer care starts to depend on regulated cell-processing logistics, clinical manufacturing capacity, traceability, and reimbursement models that can handle individualized therapeutic products.
ДіяTrack which oncology platforms can turn patient-specific cell processing into reliable, auditable, and scalable clinical infrastructure.